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 Cerebral cavernous malformations (CCM; OMIM 
116860, 603284, 603285) are composed of enlarged, 
blood-filled endothelial compartments within the ve-
nous-capillary vascular bed of the central nervous system. 
These multilobulated, often calcified vascular balls are 
characterized by a dysfunctional blood-brain barrier and 
leakiness due to insufficient tight and adherens junctions 
of the lining endothelial cells. They lack pericytes and vas-
cular smooth muscle cells, and blood flow is low. How-
ever, recurrent and larger haemorrhages into the neigh-
bouring brain parenchyma may lead to seizures and 
stroke-like symptoms such as (hemi)paresis, paraesthe-
sias, visual disturbances, vertigo, and headaches depend-
ing on their extent and localization.
 3T MRI is established as the gold standard for CCM 
detection. T2-weighted images reveal the characteristic 
mulberry- or popcorn-like appearance and a dark rim 
due to hemosiderin deposition after repeated bleedings 
( Fig. 1 ). Increased sensitivity can be achieved with T2 * -
weighted gradient echo sequences and susceptibility-
weighted images for early detection of small Zabramski 
type IV cerebral cavernomas, e.g., in the autosomal dom-
inantly inherited familial form of CCM [Zabramski et al., 
1994; Batra et al., 2009; Akers et al., 2017].
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 Abstract 
 Based on the latest gnomAD dataset, the prevalence of 
symptomatic hereditary cerebral cavernous malformations 
(CCMs) prone to cause epileptic seizures and stroke-like 
symptoms was re-evaluated in this review and calculated to 
be 1: 5,400–1: 6,200. Furthermore, state-of-the-art molecular 
genetic analyses of the known  CCM loci are described which 
reach an almost 100% mutation detection rate for familial 
CCMs if whole genome sequencing is performed for seem-
ingly mutation-negative families. An update on the spec-
trum of  CCM1 ,  CCM2 , and  CCM3  mutations demonstrates 
that deep-intronic mutations and submicroscopic copy-
number neutral genomic rearrangements are rare .  Finally, 
this review points to current guidelines on genetic counsel-
ling, neuroimaging, medical as well as neurosurgical treat-
ment and highlights the formation of active patient organi-
zations in various countries.  © 2018 S. Karger AG, Basel 
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 CCM Prevalence on the Basis of Large Genetic 
Databases 
 Next to developmental venous anomalies, CCMs have 
been reported to be the second most prevalent type of vas-
cular malformation of the central nervous system [Batra 
et al., 2009]. In a retrospective analysis of 24,535 autopsies, 
Otten et al. [1989] identified a total of 131 CCM carriers 
(1: 187; 0.53%). A similar prevalence rate was found in a 
prospective imaging study of adults aged 50–89 years that 
had been enrolled between 2004 and 2015 in the Mayo 
Clinic Study of Aging [Flemming et al., 2017]: CCMs were 
identified in 12 of 2.715 participants (1: 226; 0.44%) by 
brain MRI on a 3T system. Multiple CCMs without asso-
ciated developmental venous anomalies – an angioarchi-
tectonic constellation suggestive of familial CCM – were 
identified in only 2 probands that were asymptomatic at 
the time of research MRI (1: 1,358; 0.07%) [Flemming et 
al., 2017]. The proportion ( n = 2/12; 17%) corresponds to 
a prospective, population-based cohort study in which 24 
out of 139 (17%) adults with CCMs had multiple lesions 
[Al-Shahi Salman et al., 2012]. However, neither family 
history nor molecular genetic analyses have been docu-
mented for these cases with multiple CCMs.
 In February 2017, official access to the Genome Aggre-
gation Database (gnomAD; version 2.0), an extension of 
the Exome Aggregation Consortium (ExAC) browser 
[Lek et al., 2016], became available. This dataset contains 
123,136 exome and 15,496 whole-genome sequences of 
individuals that originate from various ethnicities (East 
Asian, South Asian, non-Finnish European, Finnish, Ash-
kenazi Jewish, Latino, and African/African American).
 Currently, 36 carriers of heterozygous frameshift, 
nonsense, and splice site mutations in the  CCM genes are 
listed in the gnomAD database ( Table 1 ). 13 of the 32 dis-
tinct mutations in  CCM1  (12/22),  CCM2  (1/9), and  CCM3 
(0/1) have previously been identified in CCM families 
from different ethnicities and are already listed in the Hu-
man Gene Mutation Database as pathogenic (HGMD 
2017.2). One of these ( CCM1 : c.1363C>T, p.Gln455 * ) 
was detected in a proband of the Latino cohort and is a 
common Hispanic founder mutation in south western re-
gions of the USA [Sahoo et al., 1999]. Given a total num-
ber of 138,632 probands within gnomAD and a sufficient 
sequencing coverage, a mutation carrier frequency of 
1: 3,851 ( ∼ 0.03%) can be calculated, which is slightly low-
er than in the smaller ExAC database (1: 3,373) [Spieg-
ler et al., 2016]. Although information on high-resolu-
tion neuroimaging is not available from the aggregated 
gnomAD dataset, hereditary CCM can be assumed for 
these mutation carriers. However, these frequencies like-
ly do not reflect the overall prevalence of familial CCM. 
Since symptomatic CCM patients often present with a 
striking clinical phenotype, loss-of-function mutation 
carriers listed in gnomAD might primarily represent in-
dividuals with asymptomatic CCMs and onset of the dis-
ease later in life. On the assumption that CCM muta-
tion carriers with an onset of CCM disease in childhood 
would not have been included in gnomAD, the overall 
prevalence of hereditary CCM can be extrapolated from 
this dataset to be in the range of approximately 1: 3,300–
1: 3,800 since one third of CCM probands are minors and 
every fifth is under the age of 10 [Spiegler et al., 2014]. 
Although this estimation might be rather rough and ig-
nores  CCM1–3 CNVs and the possibility of pathogenic 
missense variants, it is in agreement with the assumption 
that 6–7% of all CCM cases are hereditary [Batra et al., 
2009]. The prevalence of symptomatic mutation carriers 
will be even lower (roughly 1: 5,400–1: 6,200) as CCM 
penetrance is incomplete and has been reported to be 
62.2% [Denier et al., 2006]. By definition, familial CCM 
is therefore a rare disease.
 The gnomAD dataset does also reflect the locus-spe-
cific penetrance of familial CCM. While 24  CCM1 muta-
tion carriers are listed here, only a single proband with a 
heterozygous  CCM3 splice site mutation was identified 
( Table 1 ). This uneven distribution between pathogenic 
variants in  CCM1 ,  CCM2 , and  CCM3 demonstrates that 
the latter is less tolerant to mutations and supports the 
A B
 Fig. 1. T1-weighted ( A ) and T2-weighted ( B ) MRI of a 25-year-old 
proband with a cavernous malformation in his left posterior pari-
etal lobe (red arrows). The Zabramski type II CCM with a maxi-
mum diameter of 23 mm shows the typical popcorn-like appear-
ance and mixed signal intensities. The surrounding dark rim in T1 
and T2 imaging is due to hemosiderin deposits. 
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observation that  CCM3 mutation carriers often manifest 
earlier in life with a more severe phenotype [Denier et al., 
2006, Cigoli et al., 2014, Spiegler et al., 2014, Shenkar et 
al., 2015].
 Molecular Genetic Analyses: From Stepwise 
Conventional Sequencing to Comprehensive NGS 
Gene Panels and Whole Genome Sequencing 
 The identification of a pathogenic variant in either 
 CCM1  ( KRIT1 ; Laberge-le Couteulx et al. [1999]; Sahoo 
et al. [1999]),  CCM2  (Malcavernin;  OSM ; Liquori et al. 
[2003]; Denier et al. [2004a]) or  CCM3 ( PDCD10 , 
 TFAR15 ; Bergametti et al. [2005]) is essential to confirm 
the diagnosis of hereditary CCM and to guide genetic 
counselling for at-risk family members. Since mutational 
hot spots in the 3 genes cannot be defined ( Fig. 2 ), a step-
wise screening approach is generally not reasonable any 
more unless an individual has Hispanic ancestry of Mex-
ican or southwest US-American descent [Akers et al., 
2017] or originates from the Ashkenazi-Jewish popula-
tion [Gallione et al., 2011]. Therefore, CCM molecular 
genetic analyses currently include targeted capture of all 
coding exons and exon/intron junctions followed by 
massively parallel sequencing and deletion/duplication 
Table 1.  Loss-of-function mutations in CCM1, CCM2, and CCM3 that are currently listed in gnomAD
Gene Nucleotide change Predicted protein
change
Molecular
mechanism
Hetero-
zygotes, n
Reference
CCM1 
(LRG_650t1)
c.141_145delAAAGA p.Arg49Glufs*13 frameshift 1 n.d.
c.146_147delGA p.Arg49Lysfs*14 frameshift 2 Posey et al., 2017
c.151A>T p.Lys51* stop gained 1 n.d.
c.175C>T p.Gln59* stop gained 1 n.d.
c.196C>T p.Gln66* stop gained 1 Gianfrancesco et al., 2007
c.250C>T p.Gln84* stop gained 1 n.d.
c.262+1G>T p.? splice donor 1 n.d.
c.418C>T p.Arg140* stop gained 1 Melis et al., 2014
c.457dupA p.Thr153Asnfs*10 frameshift 1 Riant et al., 2013
c.535C>T p.Arg179* stop gained 1 Cavé-Riant et al., 2002
c.870dupT p.Pro291Serfs*8 frameshift 2 n.d.
c.880C>T p.Arg294* stop gained 1 Riant et al., 2013
c.1109delT p.Ile370Lysfs*6 frameshift 1 n.d.
c.1147–2A>G splice acceptor 1 n.d.
c.1363C>T p.Gln455* stop gained 1 Sahoo et al., 1999
c.1360_1363delTCTC p.Ser454Lysfs*40 frameshift 1 Cavé-Riant et al., 2002
c.1411+2T>A p.? splice donor 1 n.d.
c.1498C>T p.Gln500* stop gained 1 Riant et al., 2013
c.1563+1G>A splice donor 1 de Vos et al., 2017
c.1688_1689delAT p.Tyr563Trpfs*4 frameshift 1 Denier et al., 2004b
c.1717_1720delCAAG p.Gln573Valfs*3 frameshift 1 Limaye et al., 2007
c.1933_1936dupTTTA p.Thr646Ilefs*10 frameshift 1 n.d.
CCM2 
(LRG_664t2)
c.55C>T p.Arg19* stop gained 1 Verlaan et al., 2004
c.472+1G>A p.? splice donor 1 n.d.
c.472+1G>C p.? splice donor 3 n.d.
c.495delC p.Ser166Alafs*48 frameshift 1 n.d.
c.803+1G>C p.? splice donor 1 n.d.
c.805dupT p.Cys269Leufs*4 frameshift 1 n.d.
c.1017delG p.Gln340Serfs*14 frameshift 1 n.d.
c.1040_1044delAGTTC p.Lys347Thrfs*11 frameshift 1 n.d.
c.1234dupC p.Arg412Profs*9 frameshift 1 n.d.
CCM3 
(LRG_651t1)
c.97–1G>A p.? splice acceptor 1 n.d.
 Mutations listed as low-confidence variants in the gnomAD browser have not been included. n.d., not described in the litera-
ture.
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screening of  CCM1–3 . Sequence variants identified by 
NGS are currently still confirmed by Sanger sequencing, 
although the quality of NGS and the target enrichment 
efficiency have improved over the last years and even 
hard-to-sequence regions such as the 5 ′ -untranslated re-
gion of  CCM2 which is known for its high GC content can 
be sufficiently covered if the panel is appropriately de-
signed. In our experience, CNVs can also reliably be de-
tected from NGS data in a streamlined workflow ( Fig. 3 ). 
A further advantage of comprehensive NGS panels is that 
the parallel analysis of all 3  CCM genes facilitates the in-
terpretation of rare variants of uncertain significance: An 
alternative molecular basis for CCM – i.e., a clearly patho-
genic loss-of-function mutation in another  CCM gene – is 
supporting evidence against the pathogenicity of a vari-
ant of uncertain significance [Schröder et al., 2014; Rich-
ards et al., 2015].
 The mutation detection rate in a diagnostic context is 
highly dependent on the inclusion criteria which have 
been specified in Akers et al. [2017] and the scope of the 
analysis. Pathogenic variants can be identified in 87–98% 
of all cases with a positive family history [Denier et al., 
2006; Stahl et al., 2008; Cigoli et al., 2014; Spiegler et al. 
2014]. For apparently mutation-negative familial cases, 
pathogenic variants outside of the immediate diagnostic 
target region have been discussed. Since the thorough 
study of Denier et al. [2006], additional transcript analy-
ses and cDNA sequencing led to the identification of 
a deep intronic  CCM1 mutation (c.262+132_262+
133delAA) in an individual of the French cohort who pre-
sented with developmental delay and 4 hemispheric CCM 
lesions that had been incidentally identified by MRI. This 
intronic deletion leads to the insertion of a 99 bp pseudo-
exon with a premature stop codon in the open reading 
frame and was also detected in his mother’s and maternal 
grandfather’s blood samples. Despite multiple cavernous 
lesions, both had no symptoms suggestive of CCM either 
[Riant et al., 2014]. Nevertheless, the clinical outcome of 
 Fig. 2. Spectrum and distribution of known mutations in  CCM1 , 
 CCM2 , and  CCM3 . The organization of the main transcripts is 
schematically depicted with blue boxes indicating protein coding 
exons, clear boxes representing non-coding exons, and blue lines 
indicating intronic sequences [exon numbering according to the 
locus reference genomic (LRG) database]. The last coding nucleo-
tide of each exon is given below each box. Nonsense, frameshift, 
missense, and splice site mutations listed in HGMD 2017.2 are 
depicted in the upper part of each subpanel. Small deletions, inser-
tions and indel variants that affect splicing have been classified as 
splice mutations. ATG, start codon; TGA, stop codon. Large dele-
tions and insertions are not included. 
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individuals with deep intronic splice mutations cannot be 
predicted from the specific genotype. We have recently 
found the same intronic  CCM1 deletion in an individual 
who presented with multiple CCMs and a brainstem 
haemorrhage (unpublished data). Although deep intron-
ic splice mutations are a conceivable cause of CCM, a sys-
tematic NGS-based search did not reveal further patho-
genic variants deep within the non-coding regions of 
CCM1–3 in our cohort and is therefore not part of the 
standard diagnostic work-up yet [Rath et al., 2017].
 Our previous calculations regarding the mutation de-
tection rate included one case that remained unsolved af-
ter conventional diagnostic analyses as well as NGS of the 
entire genomic  CCM1–3 regions [Stahl et al., 2008; Spieg-
ler et al., 2014; Rath et al., 2017]. Whole exome sequenc-
ing [Spiegler et al., 2016] and whole genome sequencing 
using filter strategies for autosomal dominant and reces-
sive inheritance as well as de novo mutations in a trio-
based approach (unpublished data) did not reveal a ge-
netic cause for her disease either. The currently 19-year-
old woman first presented at the age of 5 years with 
seizures and a single supratentorial cavernous lesion that 
was neurosurgically resected and diagnosed as being a 
CCM histologically. She was referred to molecular genet-
ics 3 years later since her father was reported to have had 
2 intracranial bleedings at the age of 16 and 23 which had 
led to a major neurosurgical intervention in 1981. In light 
of the extensive negative genetic screening results as well 
as the fact that positive neuroimaging rather than positive 
family history is a more specific criterion for proven fa-
miliarity in a research context, somatic mosaicism in the 
daughter and a phenocopy or an alternative vascular mal-
formation (e.g., venous, arteriovenous, or mixed vascular 
lesions) in the father may have to be considered in this 
family.
 Given the exceptionally high mutation detection rates 
for familial CCM, the existence of a possible fourth gene 
harbouring germline mutations in individuals affected 
with CCM becomes rather unlikely 12 years after the 
identification of  CCM3 [Bergametti et al., 2005]. The 
very few remaining seemingly  CCM1–3 mutation-nega-
tive families with positive neuroimaging over several 
A
B
 Fig. 3. Comprehensive genetic screening of  CCM1–3 by targeted 
capture enrichment and NGS.  A Representative diagnostic NGS 
data from our own cohort (unpublished data). The read depth 
across the coding regions of  CCM2 is shown as coverage plot (dark 
blue); exon-intron structures of the ENSEMBL-listed  CCM2 tran-
scripts are shown below. A chromosome ideogram with the cyto-
genetic location of  CCM2 (red line) is depicted in the upper part 
and the GC content is illustrated with CpG islands in the lower 
part.  B Representative NGS-based CNV analysis demonstrating a 
heterozygous deletion of exon 8 and 9 of  CCM3 . 
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generations may rather carry a pathogenic variant out-
side the routinely screened exonic regions and immedi-
ate adjacent splice sites of the 3 known  CCM genes or a 
copy number neutral genomic rearrangement involving 
either the  CCM1 ,  CCM2 , or  CCM3 gene. Most recently, 
we have clarified such a familial case in which only whole 
genome sequencing combined with an excellent bioin-
formatics pipeline resulted in the identification of a 24-
kb spanning inversion involving exon 1 of  CCM2 [Spie-
gler et al., 2017].
 Detection of High-Level Mosaicism and Low-Level 
Somatic Mutations with NGS 
 Similar to familial CCM, the detection rate for isolated 
cases with multiple CCMs depends on the inclusion cri-
teria and mutation detection methods used. Previously, it 
ranged from 57 to 60% [Denier et al., 2006; Stahl et al., 
2008; Spiegler et al., 2014]. However, the guidelines pub-
lished by Akers et al. in 2017 ( Table 2 ) recommend to in-
clude only those that neither present with an associated 
developmental venous anomaly [Dammann et al., 2017] 
nor with a history of brain radiation as this is a known risk 
factor for CCM formation [Heckl et al., 2002; Nimjee et 
al., 2006]. Following these recommendations, mutation 
detection rates higher than 75% appear to be realistic [Ak-
ers et al., 2017].
 In light of incomplete CCM penetrance, a lack of neu-
rological symptoms is insufficient to exclude CCM for 
at-risk family members. Targeted sequencing of DNA 
samples of both parents should be offered as part of the 
diagnostic work-up for apparently isolated CCM cases. 
Since parents do not always consent to predictive genetic 
testing, de novo mutations in  CCM1–3 might not be as 
rare as previously thought [Lucas et al., 2001; Bergametti 
et al., 2005; Liquori et al., 2006; Stahl et al., 2008; Riant et 
al., 2013; Cigoli et al., 2014; Shenkar et al., 2015; Rath et 
al., 2016]. NGS data may indicate mosaicism, but high 
coverage and a sophisticated validation are necessary for 
reliable clinical conclusions [Acuna-Hidalgo et al., 2015]. 
Consistent with literature reports, our experience sug-
gests that  CCM3 might be more prone to de novo muta-
tional events than  CCM1 and  CCM2 . Recently, we have 
identified another  CCM3 de novo point mutation in a 
2-year-old boy with global developmental delay, multiple 
CCMs, and a brainstem haemorrhage. The  CCM3 splice 
mutation (c.474+5G>A) was detected with an alternate 
allele read frequency of 33–35% in lymphocyte and buc-
cal mucosa DNA in independent NGS approaches and 
had most likely originated from an early postzygotic mu-
tational event. Mosaicism was also suspected for a  CCM3 
gene deletion in another CCM case based on MLPA re-
sults [Rath et al., 2016]. Although the discrimination be-
tween germline mutation and high-level mosaicism 
might be of minor clinical relevance for the index case, it 
is important for genetic counselling of his/her relatives.
 Not only high-level mosaicism, but also the other end 
of the spectrum – namely, low-level somatic mutations in 
CCM lesions – remain analytically challenging. In agree-
ment with the hypothesis of a Knudsonian 2-hit mecha-
nism, immunohistochemical analyses of cavernous le-
sions of 7 unrelated  CCM1 ,  CCM2 , and  CCM3 mutation 
carriers demonstrated loss of function for the corre-
sponding CCM protein in cavernous, but not adjacent 
endothelial cells [Knudson, 1971; Pagenstecher et al., 
2009]. Furthermore, biallelic somatic and germline muta-
tions have been identified on nucleotide level in CCM le-
sions of familial cases with known pathogenic  CCM1–3 
variants [Gault et al., 2005, 2009; Akers et al., 2009]. So-
matic mosaicism is also an explanation for isolated CCM 
cases without a known germline mutation. McDonald et 
al. [2014] have successfully identified somatic variants in 
4 out of 11 sporadic CCM samples with NGS analyses. 
Notably, 2  CCM1 nonsense mutations that had been de-
tected in one of these lesions were located in trans and 
demonstrated that 2 biallelic somatic mutations in cav-
ernous endothelial cells are a possible explanation for 
mutation-negativity in standard molecular diagnostics 
[McDonald et al., 2014]. However, the validity of somatic 
mutations as the sole “second hit” mechanism in CCM 
pathogenesis is under debate as such variants cannot be 
identified in all CCM lesions and some of the mutations 
identified so far are in-frame deletions that cannot be 
classified as bona fide loss-of-function variants [Reich et 
al., 2003; Marini et al., 2004; McDonald et al., 2014]. Fu-
ture studies with high-sensitivity techniques are neces-
sary to address this open question in larger CCM cohorts.
Table 2.  Inclusion criteria for diagnostic molecular genetic testing 
of CCM carriers
Positive family history
Multiple CCMs without
• associated developmental venous anomaly or
• history of brain radiation
 Data based on Akers et al. [2017]. CCM, cerebral cavernous 
malformation.
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 Future Perspectives: How Genetic and 
Environmental Factors May Modify the CCM 
Phenotype 
 As mentioned above, the course of the disease can vary 
significantly between individuals that share the same 
germline mutation even within a single CCM family [Lu-
cas et al., 2003; Spiegler et al., 2014; Fauth et al., 2015]. 
Given that a second somatic mutation cannot be identi-
fied in all cases, it is reasonable to hypothesize that yet to 
be identified regulatory mechanisms and different ex-
pression levels of modifier genes may also trigger disease 
onset and contribute to incomplete disease penetrance 
and variable expressivity of CCM. Anticipation with re-
spect to age of disease onset has been reported in some 
CCM families [Siegel et al., 1998a, b]. However, trinucle-
otide-repeat expansions do not belong to the mutation 
spectrum associated with CCM ( Fig.  2 ). Furthermore, 
Netzer and colleagues [2009] found no evidence for pro-
gressive telomere shortening in  CCM1 mutation carriers 
from a 3-generation family presenting with significantly 
earlier disease onset in the youngest generation [Kuhn et 
al., 2009].
 Genetic Counselling, Current Guidelines, and Patient 
Organizations 
 Owing to the increasing availability of high-resolution 
brain imaging, a growing number of asymptomatic intra-
cerebral cavernous malformations are currently identi-
fied incidentally. The haemorrhage rate per patient-year 
has been reported to be significantly lower in incidentally 
discovered groups when compared to symptomatic 
groups [Washington et al., 2010; Al-Holou et al., 2012; 
Al-Shahi Salman et al., 2012; Gross et al., 2016; Horne et 
al., 2016; Akers et al., 2017]. In a single-centre cohort of 
107 individuals with CCM as an incidental finding, the 
only patient in whom a prospective haemorrhage was de-
finitively related to the cavernous malformation was in 
fact diagnosed as having a familial form of CCM. It was 
concluded that the risk of future haemorrhage is low in 
patients presenting with an incidental CCM [Moore et al., 
2014]. For familial CCM, higher annual haemorrhage 
rates, the occurrence of multiple CCMs at an earlier age, 
and the appearance of new lesions have been reported 
[Zabramski et al., 1994; Labauge et al., 2001; Shenkar et 
al., 2015].
 Inclusion criteria for diagnostic molecular genetic 
testing are listed in  Table 2 . The question of predictive 
analyses for at-risk relatives needs to be carefully dis-
cussed during genetic counselling. Obviously, exclusion 
of a pathogenic familial variant is the main potential ad-
vantage of predictive testing since it relieves relatives 
from uncertainties on the occasion of e.g. ordinary head-
aches, dizziness, or discomfort unrelated to CCM and 
renders neurological examinations and repeated brain 
imaging unnecessary. On the other hand, confrontation 
with a  CCM mutation may enhance anxieties and war-
rants an MRI including gradient echo or susceptibility-
weighted sequences in order to document the number, 
location, and stage of cavernous lesions. Follow-up MRI 
is recommended within 2 weeks after the onset or wors-
ening of clinical symptoms [Akers et al., 2017]. Two out 
of 33 asymptomatic individuals with familial CCMs 
(range 1–85 lesions/individual) became symptomatic in 
a prospective 2-year follow-up study: One experienced a 
sudden haemorrhage within the brainstem, the other par-
tial seizures [Labauge et al., 2001].
 Mutation carriers should be informed that about 40% 
of  CCM1–3 mutation carriers remain asymptomatic [De-
nier et al., 2006]. In addition, inter- and intrafamilial phe-
notypic variability is high and fulminant clinical courses 
of CCM are rather rare. An earlier and more severe dis-
ease manifestation has been reported for  CCM3 mutation 
carriers when compared to  CCM1 and  CCM2 mutation 
carriers [Denier et al., 2006; Cigoli et al., 2014; Spiegler et 
al., 2014]. In a cohort of 18  CCM3 mutation carriers, the 
mean age at symptom onset was 12.6 years (range 0.25–52 
years) as opposed to a mean age at first overt haemor-
rhage of 30 years for familial cases carrying a  CCM1 or 
 CCM2 mutation (range 1–52 years) [Shenkar et al., 2015]. 
However, even with an increased lesion burden of more 
than 30 cavernomas,  CCM3 mutation carriers may re-
main asymptomatic until the fifth decade but need to be 
prepared that they may develop a severe phenotype in-
cluding dysarthria, multiple cranial nerve palsies, gait dis-
turbances, and focal seizures later in life [Schröder et al., 
2014]. Seizures are the predominant first symptom of su-
pratentorial lobar CCMs, while brainstem lesions are pri-
marily associated with cranial nerve palsy, hemiparesis, 
and other focal neurological deficits. Prior haemorrhage 
and brainstem location appear to confer a higher risk for 
symptomatic haemorrhage, while the annual re-hemor-
rhage rate has been reported to decline over time [Al-
Holou et al., 2012; Al-Shahi Salman et al., 2012; Gross et 
al., 2016; Horne et al., 2016; Gross and Du, 2017].
 In spite of the growing knowledge on CCM patho-
physiology, most clinical treatment decisions are still 
based on expert opinions and an individual risk-benefit 
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analysis. The synopsis of guidelines that has recently been 
published by the American Angioma Alliance provides a 
useful roadmap for clinical CCM management, although 
high-level recommendations are still missing due to the 
lack of randomized and sufficiently powered clinical tri-
als [Akers et al., 2017].
 Patient organizations like the American Angioma Al-
liance (http://www.angiomaalliance.org/), the Caverno-
ma Alliance UK (https://www.cavernoma.org.uk/), the 
German “Bundesverband Angeborene Gefässfehlbildun-
gen” (http://www.angiodysplasie.de/de/; http://www.ka-
vernom.de/de/) and other national and international or-
ganizations are important partners to exchange experi-
ences and provide support regarding personal, social, 
psychological, and medical issues that arise with the diag-
nosis of a rare disease such as familial CCM. In addition, 
these networks are extremely helpful because they main-
tain long-term contact between affected individuals and 
their families and communicate results from ongoing 
therapy studies back to patients.
 Conclusion 
 With a calculated prevalence of 1: 5,400–1: 6,200, symp-
tomatic hereditary CCMs belong to the group of rare dis-
eases that can be transmitted in an autosomal dominant 
manner with incomplete penetrance and variable expres-
sivity. A mutation detection rate of close to 100% can be 
achieved if extensive molecular genetic analyses are per-
formed to screen for deep intronic mutations as well as 
copy-number neutral submicroscopic genomic rear-
rangements within the  CCM1–3 loci. Stringent inclusion 
criteria are equally important and include high-resolu-
tion MRI with T2 * -weighted gradient echo sequences 
and susceptibility-weighted images of parents in order to 
select the optimal filter strategy after whole exome or ge-
nome sequencing in a research context. The identifica-
tion of a  CCM1–3 mutation influences medical manage-
ment which is still based on expert opinions and individ-
ual risk-benefit analyses as outlined in the 2017 consensus 
recommendations of the Angioma Alliance Scientific Ad-
visory Board Clinical Experts Panel.  
 Acknowledgements 
 This work was supported by the Deutsche Forschungsgemein-
schaft (DFG) (grant DFG-FE432/9-1 to U.F. and grant DFG-
RA2876/2-1 to M.R.) and by the Research Network Molecular 
Medicine of the University Medicine Greifswald (grant FOMM-
2017-03 to S.S.). The authors would like to thank gnomAD and the 
groups that provided exome and genome variant data to this re-
source. A full list of contributing groups can be found at http://
gnomad.broadinstitute.org/about.
 Disclosure Statement 
 The authors declare no conflicts of interest.
 
 References 
 Acuna-Hidalgo R, Bo T, Kwint MP, van de Vorst 
M, Pinelli M, et al: Post-zygotic point muta-
tions are an underrecognized source of de 
novo genomic variation. Am J Hum Genet 97: 
 67–74 (2015). 
 Akers A, Al-Shahi Salman R, A Awad I, Dahlem 
K, Flemming K, et al: Synopsis of Guidelines 
for the Clinical Management of Cerebral Cav-
ernous Malformations: Consensus Recom-
mendations Based on Systematic Literature 
Review by the Angioma Alliance Scientific 
Advisory Board Clinical Experts Panel. Neu-
rosurgery 80: 665–680 (2017). 
 Akers AL, Johnson E, Steinberg GK, Zabramski 
JM , Marchuk DA: Biallelic somatic and 
germline mutations in cerebral cavernous 
malformations (CCMs): evidence for a two-
hit mechanism of CCM pathogenesis. Hum 
Mol Genet 18: 919–930 (2009). 
 Al-Holou WN, O’Lynnger TM, Pandey AS, Gem-
mete JJ, Thompson BG, et al: Natural history 
and imaging prevalence of cavernous malfor-
mations in children and young adults. J Neu-
rosurg Pediatr 9: 198–205 (2012). 
 Al-Shahi Salman R, Hall JM, Horne MA, Moultrie 
F, Josephson CB, et al: Untreated clinical 
course of cerebral cavernous malformations: 
a prospective, population-based cohort study. 
Lancet Neurol 11: 217–224 (2012). 
 Batra S, Lin D, Recinos PF, Zhang J, Rigamonti D: 
Cavernous malformations: natural history, 
diagnosis and treatment. Nat Rev Neurol 5: 
 659–670 (2009). 
 Bergametti F, Denier C, Labauge P, Arnoult M, 
Boetto S, et al: Mutations within the pro-
grammed cell death 10 gene cause cerebral 
cavernous malformations. Am J Hum Genet 
76: 42–51 (2005). 
 Cavé-Riant F, Denier C, Labauge P, Cécillon M, 
Maciazek J, et al: Spectrum and expression 
analysis of  KRIT1  mutations in 121 consecu-
tive and unrelated patients with cerebral cav-
ernous malformations. Eur J Hum Genet 10: 
 733–740 (2002). 
 Cigoli MS, Avemaria F, De Benedetti S, Gesu GP, 
Accorsi LG, et al:  PDCD10 gene mutations in 
multiple cerebral cavernous malformations. 
PLoS One 9:e110438 (2014). 
 Dammann P, Wrede K, Zhu Y, Matsushige T, 
Maderwald S, et al: Correlation of the venous 
angioarchitecture of multiple cerebral cav-
ernous malformations with familial or spo-
radic disease: a susceptibility-weighted imag-
ing study with 7-Tesla MRI. J Neurosurg 126: 
 570–577 (2017). 
 Denier C, Goutagny S, Labauge P, Krivosic V, Ar-
noult M, et al: Mutations within the  MGC4607 
 gene cause cerebral cavernous malforma-
tions. Am J Hum Genet 74: 326–337 (2004a). 
 Spiegler/Rath/Paperlein/Felbor
 
Mol Syndromol 2018;9:60–69
DOI: 10.1159/000486292
68
 Denier C, Labauge P, Brunereau L, Cavé-Riant F, 
Marchelli F, et al: Clinical features of cerebral 
cavernous malformations patients with 
 KRIT1  mutations. Ann Neurol 55: 213–220 
(2004b). 
 Denier C, Labauge P, Bergametti F, Marchelli F, 
Riant F, et al: Genotype-phenotype correla-
tions in cerebral cavernous malformations 
patients. Ann Neurol 60: 550–556 (2006). 
 de Vos IJ, Vreeburg M, Koek GH, van Steensel 
MA: Review of familial cerebral cavernous 
malformations and report of seven additional 
families. Am J Med Genet A 173: 338–351 
(2017). 
 Fauth C, Rostasy K, Rath M, Gizewski E, Lederer 
AG, et al: Highly variable intrafamilial mani-
festations of a  CCM3  mutation ranging from 
acute childhood cerebral haemorrhage to 
late-onset meningiomas. Clin Neurol Neuro-
surg 128: 41–43 (2015). 
 Flemming KD, Graff-Radford J, Aakre J, Kantarci 
K, Lanzino G, et al: Population-based preva-
lence of cerebral cavernous malformations in 
older adults: Mayo Clinic Study of Aging. 
JAMA Neurol 74: 801–805 (2017). 
 Gallione CJ, Solatycki A, Awad IA, Weber JL, 
Marchuk DA: A founder mutation in the Ash-
kenazi Jewish population affecting messenger 
RNA splicing of the  CCM2  gene causes cere-
bral cavernous malformations. Genet Med 13: 
 662–666 (2011). 
 Gault J, Shenkar R, Recksiek P, Awad IA: Biallelic 
somatic and germ line  CCM1  truncating mu-
tations in a cerebral cavernous malformation 
lesion. Stroke 36: 872–874 (2005). 
 Gault J, Awad IA, Recksiek P, Shenkar R, Breeze 
R, et al: Cerebral cavernous malformations: 
somatic mutations in vascular endothelial 
cells. Neurosurgery 65: 138–144 (2009). 
 Gianfrancesco F, Cannella M, Martino T, 
Maglione V, Esposito T, et al: Highly variable 
penetrance in subjects affected with cavern-
ous cerebral angiomas (CCM) carrying novel 
 CCM1  and  CCM2  mutations. Am J Med Gen-
et B Neuropsychiatr Genet 144B:691–695 
(2007). 
 Gross BA, Du R: Hemorrhage from cerebral cav-
ernous malformations: a systematic pooled 
analysis. J Neurosurg 126: 1079–1087 (2017). 
 Gross BA, Du R, Orbach DB, Scott RM, Smith ER: 
The natural history of cerebral cavernous 
malformations in children. J Neurosurg Pedi-
atr 17: 123–128 (2016). 
 Heckl S, Aschoff A, Kunze S: Radiation-induced 
cavernous hemangiomas of the brain: a late 
effect predominantly in children. Cancer 94: 
 3285–3291 (2002). 
 Horne MA, Flemming KD, Su IC, Stapf C, Jeon 
JP, et al: Clinical course of untreated cerebral 
cavernous malformations: a meta-analysis of 
individual patient data. Lancet Neurol 15: 
 166–173 (2016). 
 Knudson AG Jr: Mutation and cancer: statistical 
study of retinoblastoma. Proc Natl Acad Sci 
USA 68: 820–823 (1971). 
 Kuhn J, Brummendorf TH, Brassat U, Lehnhardt 
FG, Chung BD, et al: Novel  KRIT1  mutation 
and no molecular evidence of anticipation in 
a family with cerebral and spinal cavernous 
malformations. Eur Neurol 61:  154–158 
(2009). 
 Labauge P, Brunereau L, Laberge S, Houtteville 
JP: Prospective follow-up of 33 asymptomatic 
patients with familial cerebral cavernous mal-
formations. Neurology 57: 1825–1828 (2001). 
 Laberge-le Couteulx S, Jung HH, Labauge P, 
Houtteville JP, Lescoat C, et al: Truncating 
mutations in  CCM1 , encoding  KRIT1 , cause 
hereditary cavernous angiomas. Nat Genet 
23: 189–193 (1999). 
 Lek M, Karczewski KJ, Minikel EV, Samocha KE, 
Banks E, et al: Analysis of protein-coding ge-
netic variation in 60,706 humans. Nature 536: 
 285–291 (2016). 
 Limaye N, Revencu N, Van Regemorter N, Gar-
zon M, Bonduelle M, et al: Novel human path-
ological mutations. Gene symbol:  KRIT1 . 
Disease: cerebral cavernous malformation. 
Hum Genet 122: 552 (2007). 
 Liquori CL, Berg MJ, Siegel AM, Huang E, Zawis-
towski JS, et al: Mutations in a gene encoding 
a novel protein containing a phosphotyro-
sine-binding domain cause type 2 cerebral 
cavernous malformations. Am J Hum Genet 
73: 1459–1464 (2003). 
 Liquori CL, Berg MJ, Squitieri F, Ottenbacher M, 
Sorlie M, et al: Low frequency of  PDCD10 
mutations in a panel of  CCM3 probands: po-
tential for a fourth  CCM  locus. Hum Mutat 
27: 118 (2006). 
 Lucas M, Costa AF, Montori M, Solano F, Zayas 
MD, Izquierdo G: Germline mutations in the 
 CCM1 gene, encoding Krit1, cause cerebral 
cavernous malformations. Ann Neurol 49: 
 529–532 (2001). 
 Lucas M, Costa AF, Garcia-Moreno JM, Solano F, 
Gamero MA, Izquierdo G: Variable expres-
sion of cerebral cavernous malformations in 
carriers of a premature termination codon in 
exon 17 of the  Krit1  gene. BMC Neurol 3: 5 
(2003). 
 Marini V, Ferrera L, Pigatto F, Origone P, Garrè 
C, et al: Search for loss of heterozygosity and 
mutation analysis of  KRIT1  gene in CCM pa-
tients. Am J Med Genet A 130A:98–101 
(2004). 
 McDonald DA, Shi C, Shenkar R, Gallione CJ, 
Akers AL, et al: Lesions from patients with 
sporadic cerebral cavernous malformations 
harbor somatic mutations in the  CCM  genes: 
evidence for a common biochemical pathway 
for CCM pathogenesis. Hum Mol Genet 23: 
 4357–4370 (2014). 
 Melis M, Cau M, Corraine S, Secci S, Addis M, 
Melis M: Cerebral cavernous malformations 
and unilateral moyamoya in a patient with a 
new mutation in the  KRIT-1/CCM1 gene. 
Cerebrovasc Dis 38: 311–312 (2014). 
 Moore SA, Brown RD Jr, Christianson TJ, Flem-
ming KD: Long-term natural history of inci-
dentally discovered cavernous malformations 
in a single-center cohort. J Neurosurg 120: 
 1188–1192 (2014). 
 Nimjee SM, Powers CJ, Bulsara KR: Review of the 
literature on de novo formation of cavernous 
malformations of the central nervous system 
after radiation therapy. Neurosurg Focus 
21:e4 (2006). 
 Otten P, Pizzolato GP, Rilliet B, Berney J: 131 cas-
es of cavernous angioma (cavernomas) of the 
CNS, discovered by retrospective analysis of 
24,535 autopsies (in French). Neurochirurgie 
35: 82–83 (1989). 
 Pagenstecher A, Stahl S, Sure U, Felbor U: A two-
hit mechanism causes cerebral cavernous 
malformations: complete inactivation of 
CCM1, CCM2 or CCM3 in affected endothe-
lial cells. Hum Mol Genet 18: 911–918 (2009). 
 Posey JE, Harel T, Liu P, Rosenfeld JA, James RA, 
et al: Resolution of disease phenotypes result-
ing from multilocus genomic variation. N 
Engl J Med 376: 21–31 (2017). 
 Rath M, Spiegler S, Nath N, Schwefel K, Di Do-
nato N, et al: Constitutional de novo and 
postzygotic mutations in isolated cases of ce-
rebral cavernous malformations. Mol Genet 
Genomic Med 5: 21–27 (2016). 
 Rath M, Jenssen SE, Schwefel K, Spiegler S, Klei-
meier D, et al: High-throughput sequencing 
of the entire genomic regions of  CCM1/
KRIT1 ,  CCM2  and CCM3/PDCD10  to search 
for pathogenic deep-intronic splice muta-
tions in cerebral cavernous malformations. 
Eur J Med Genet 60: 479–484 (2017). 
 Reich P, Winkler J, Straube A, Steiger HJ, Peraud 
A: Molecular genetic investigations in the 
 CCM1  gene in sporadic cerebral cavernomas. 
Neurology 60: 1135–1138 (2003). 
 Riant F, Cecillon M, Saugier-Veber P, Tournier-
Lasserve E:  CCM  molecular screening in a di-
agnosis context: novel unclassified variants 
leading to abnormal splicing and importance 
of large deletions. Neurogenetics 14: 133–141 
(2013). 
 Riant F, Odent S, Cecillon M, Pasquier L, de Bara-
cé C, et al: Deep intronic  KRIT1  mutation in 
a family with clinically silent multiple cerebral 
cavernous malformations. Clin Genet 86: 
 585–588 (2014). 
 Richards S, Aziz N, Bale S, Bick D, Das S, et al: 
Standards and guidelines for the interpreta-
tion of sequence variants: a joint consensus 
recommendation of the American College of 
Medical Genetics and Genomics and the As-
sociation for Molecular Pathology. Genet 
Med 17: 405–424 (2015). 
 Sahoo T, Johnson EW, Thomas JW, Kuehl PM, 
Jones TL, et al: Mutations in the gene encod-
ing KRIT1, a Krev-1/rap1a binding protein, 
cause cerebral cavernous malformations 
(CCM1). Hum Mol Genet 8:  2325–2333 
(1999). 
 Cerebral Cavernous Malformations Mol Syndromol 2018;9:60–69
DOI: 10.1159/000486292
69
 Schröder W, Najm J, Spiegler S, Mair M, Viera J, 
et al: Predictive genetic testing of at-risk rela-
tives requires analysis of all  CCM  genes after 
identification of an unclassified  CCM1  vari-
ant in an individual affected with cerebral 
cavernous malformations. Neurosurg Rev 37: 
 161–165 (2014). 
 Shenkar R, Shi C, Rebeiz T, Stockton RA, McDon-
ald DA, et al: Exceptional aggressiveness of 
cerebral cavernous malformation disease as-
sociated with  PDCD10 mutations. Genet Med 
17: 188–196 (2015). 
 Siegel AM, Andermann E, Badhwar A, Rouleau 
GA, Wolford GL, et al: Anticipation in famil-
ial cavernous angioma: a study of 52 families 
from International Familial Cavernous An-
gioma Study. IFCAS Group. Lancet 352: 
 1676–1677 (1998a). 
 Siegel AM, Andermann F, Badhwar A, Rouleau 
GA, Dam M, et al: Anticipation in familial 
cavernous angioma: ascertainment bias or ge-
netic cause. Acta Neurol Scand 98: 372–376 
(1998b). 
 Spiegler S, Najm J, Liu J, Gkalympoudis S, 
Schröder W, et al: High mutation detection 
rates in cerebral cavernous malformation 
upon stringent inclusion criteria: one-third of 
probands are minors. Mol Genet Genomic 
Med 2: 176–185 (2014). 
 Spiegler S, Kirchmaier B, Rath M, Korenke GC, 
Tetzlaff F, et al:  FAM222B  is not a likely nov-
el candidate gene for cerebral cavernous mal-
formations. Mol Syndromol 7:  144–152 
(2016). 
 Spiegler S, Rath M, Hoffjan S, Dammann P, Sure 
U, et al: First large genomic inversion in fa-
milial cerebral cavernous malformation iden-
tified by whole genome sequencing. Neuroge-
netics, Epub ahead of print (2017). 
 Stahl S, Gaetzner S, Voss K, Brackertz B, Schleider 
E, et al: Novel  CCM1 ,  CCM2 , and  CCM3  mu-
tations in patients with cerebral cavernous 
malformations: in-frame deletion in  CCM2 
prevents formation of a CCM1/CCM2/
CCM3 protein complex. Hum Mutat 29: 709–
717 (2008). 
 Verlaan DJ, Laurent SB, Rochefort DL, Liquori 
CL, Marchuk DA, et al:  CCM2  mutations ac-
count for 13% of cases in a large collection of 
kindreds with hereditary cavernous malfor-
mations. Ann Neurol 55: 757–758 (2004). 
 Washington CW, McCoy KE, Zipfel GJ: Update 
on the natural history of cavernous malfor-
mations and factors predicting aggressive 
clinical presentation. Neurosurg Focus 29:E7 
(2010). 
 Zabramski JM, Wascher TM, Spetzler RF, John-
son B, Golfinos J, et al: The natural history of 
familial cavernous malformations: results of 
an ongoing study. J Neurosurg 80: 422–432 
(1994). 
 
